TRAUSAN

(FAES SPAIN)

Citicoline

DOSAGE FORM
Drops, oral solution.

COMPOSITION
Every 100 ml of solution contain: choline citidyl‑diphosphate (citicholine): 10 g.
Aromatized excipient q.s.
Each ml contains: 100 mg of citicholine. Contains parabens and sodium saccharin.
Does not contain saccharose.

PHARMACOLOGICAL ACTION
Citicholine is a coenzyme which favors the synthesis of lecithin and other phospholipids (among other substances), the latter being essential elements of the neuron membrane structure.
The biochemical activity of citicholine manifests particularly in situations of diminished cerebral function secondary to deficiencies in phospholipid synthesis (especially lecithin), in the context of brain damage of different causes, and in situation of cerebral involution. In these cases, citicholine regulates selective permeability, re‑establishes ion balance and activates mitochondrial and cell enzyme system function.

THERAPEUTIC INDICATIONS
TRAUSAN is indicated in all situations of diminished cerebral function secondary to deficiencies in phospholipid metabolism: cerebral atherosclerosis, anxiety‑depressive states associated with aging, speech disorders, cerebrovascular disorders and vertigo.

INTERACTION WITH OTHER DRUGS AND FOODS
Combination with meclofenoxate and L‑Dopa should beavoided.

CONTRAINDICATIONS
Cerebrovascular accidents of hemorrhagic origin. Hypersensitivity to the drug substance.

SPECIAL PRECAUTIONS FOR USE
Not applicable.

EFFECTS IN PREGNANT WOMEN, NURSING INFANTS, CHILDREN, ELDERLY INDIVIDUALS AND PATIENTS WITH SPECIAL DISORDERS
The innocuousness of citicholine during pregnancy and lactation has not been demonstrated;
consequently, the product is not indicated in such situations.

SIDE EFFECTS
There have been occasional reports of slight digestive alterations and a slight reduction in blood pressure.
Adverse reactions: should you observe any adverse reaction other than those described previously, consult your doctor or chemist.

LIST OF EXCIPIENTS
Sodium saccharin, caramel aroma, propyl p‑hydroxybenzoate (nipazol), methyl p‑hydroxybenzoate
(nipagin), potassium sorbate, propylene glycol, absolute alcohol, hydrochloric acid, purified water.

POSOLOGY, METHOD AND ROUTE OF ADMINISTRATION, AND DURATION OF TREATMENT
The posology and administration regimen should be established according to physician criterion.
In general, the following is recommended:
Adults: 100 to 200 mg (1‑2 ml), two or three times a day.
Children: 100 mg (1 ml) two or three times a day.
It is recommended to administer with precaution to children below 3 years.
Fill the dosifier with the prescribed dose (1‑2 ml) and mix the product with a little water. The duration of treatment and maximum dose should be established according to clinical criterion.

WITHDRAWAL SYMPTOMS IN THE EVENT OF TREATMENT SUSPENSION OR THE OMISSION OF ONE OR MORE DOSES
None have been described.

MEASURES TO BE ADOPTED IN THE EVENT OF OVERDOSE OR POISONING
Since the product has no toxic effects, overdose is not expected to produce serious consequences.

PATIENT RECOMMENDATIONS
Check the product expiry date.
If you experience side effects other than those described, notify your physician or pharmacist. Keep all medication out of sight and reach of children.

PRESENTATION
Bottles containing 50 ml of oral solution to be administered with the dosing syringe included in the container of the product.

SPECIAL STORAGE PRECAUTIONS
Protect from exposure to light. Store below 25° C.
Expiry: do not use Trausan after the expiry date indicated on the packaging.

Prescription drug.